{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:10:19Z","timestamp":1795047019245,"version":"4.10.2"},"reference-count":222,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS120038"],"award-info":[{"award-number":["NS120038"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS109260"],"award-info":[{"award-number":["NS109260"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG072979"],"award-info":[{"award-number":["AG072979"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG062418"],"award-info":[{"award-number":["AG062418"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG066597"],"award-info":[{"award-number":["AG066597"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13311-023-01379-z","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T12:02:14Z","timestamp":1683115334000},"page":"932-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Fluid and Biopsy Based Biomarkers in Parkinson's Disease"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-0102","authenticated-orcid":false,"given":"David G.","family":"Coughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-5098","authenticated-orcid":false,"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6645","key":"10.1007\/s13311-023-01379-z_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","article-title":"Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study","volume":"83","author":"Adler","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","article-title":"What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study","volume":"42","author":"Hughes","year":"1992","journal-title":"Neurology"},{"issue":"Pt 4","key":"10.1007\/s13311-023-01379-z_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","article-title":"The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service","volume":"125","author":"Hughes","year":"2002","journal-title":"Brain"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.43.4.829","article-title":"Prognostic significance of the onset mode in parkinsonism","volume":"43","author":"Rajput","year":"1993","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.55.7.969","article-title":"Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study","volume":"55","author":"Litvan","year":"1998","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/mds.27362","article-title":"Validation of the MDS clinical diagnostic criteria for Parkinson's disease","volume":"33","author":"Postuma","year":"2018","journal-title":"Mov Disord [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/bmm.10.90","article-title":"Quantification of \u03b1-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies","volume":"4","author":"Mollenhauer","year":"2010","journal-title":"Biomark Med [Internet]"},{"issue":"SUPPL.1","key":"10.1007\/s13311-023-01379-z_bib11","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","article-title":"Quantification of \u03b1-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?","volume":"20","author":"Mollenhauer","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"121","key":"10.1007\/s13311-023-01379-z_bib12","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci Transl Med [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/acn3.729","article-title":"Plasma alpha\u2010synuclein detected by single molecule array is increased in PD","volume":"6","author":"Ng","year":"2019","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma \u03b1-synuclein is decreased in subjects with Parkinson's disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","article-title":"The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease","volume":"87","author":"Gibbons","year":"2016","journal-title":"Neurology [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated \u03b1-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib17","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-Qu IC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-023-01379-z_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4939-9124-2_4","article-title":"Detection of misfolded \u03b1-synuclein aggregates in cerebrospinal fluid by the protein misfolding cyclic amplification platform","volume":"1948","author":"Concha-Marambio","year":"2019","journal-title":"Methods Mol Biol [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/mds.28242","article-title":"Blinded RT-QuIC analysis of \u03b1-synuclein biomarker in skin tissue from Parkinson's disease patients","volume":"35","author":"Manne","year":"2020","journal-title":"Mov Disord [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.54.10.1916","article-title":"Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease","volume":"54","author":"Hurtig","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01379-z_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2019.03.023","article-title":"Most cases with lewy pathology in a population-based cohort adhere to the braak progression pattern but \u2018failure to fit'is highly dependent on staging system applied","author":"Coughlin","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-023-01379-z_bib24","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00401-008-0409-8","article-title":"Evaluation of alpha-synuclein immunohistochemical methods used by invited experts","volume":"116","author":"Beach","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jnen\/nlz080","article-title":"Unified staging system for Lewy body disorders: clinicopathologic correlations and comparison to Braak staging","volume":"78","author":"Adler","year":"2019","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp-2020-325668","article-title":"Sex differences for phenotype in pathologically defined dementia with Lewy bodies","volume":"92","author":"Bayram","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/mds.29044","article-title":"Sex differences for clinical correlates of Alzheimer's pathology in people with Lewy body pathology","volume":"37","author":"Bayram","year":"2022","journal-title":"Mov Disord [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med"},{"issue":"3\u20134","key":"10.1007\/s13311-023-01379-z_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000113679","article-title":"Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia","volume":"5","author":"Jellinger","year":"2008","journal-title":"Neurodegener Dis"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s007020200027","article-title":"Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease","volume":"109","author":"Jellinger","year":"2002","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-023-01379-z_bib33","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00401-004-0869-4","article-title":"Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease","volume":"108","author":"Marui","year":"2004","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00401-003-0750-x","article-title":"Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study","volume":"106","author":"Wakisaka","year":"2003","journal-title":"Acta Neuropathol [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","article-title":"The progression of pathology in longitudinally followed patients with Parkinson's disease","volume":"115","author":"Halliday","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","article-title":"Parkinson disease with dementia: comparing patients with and without Alzheimer pathology","volume":"23","author":"Sabbagh","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.25392","article-title":"Cognitive and pathological influences of tau pathology in Lewy body disorders","volume":"85","author":"Coughlin","year":"2019","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's Dement [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid beta 1\u201342 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.25811","article-title":"Evolution of Alzheimer's disease cerebrospinal fluid biomarkers in early Parkinson's disease","volume":"88","author":"Irwin","year":"2020","journal-title":"Ann Neurol [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib47","series-title":"Annals of Neurology","first-page":"S56","article-title":"Antemortem CSF tau and A beta biomarkers are predictive of postmortem Alzheimer's disease pathology in autopsy-confirmed Lewy body disease","author":"Irwin","year":"2017"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","article-title":"Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies","volume":"88","author":"Lemstra","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J Alzheimer's Dis"},{"issue":"S4","key":"10.1007\/s13311-023-01379-z_bib50","article-title":"ATN classification in dementia with Lewy bodies: association with clinical profile, cognitive decline and survival","volume":"17","author":"van de Beek","year":"2021","journal-title":"Alzheimer's Dement [Internet]"},{"issue":"24","key":"10.1007\/s13311-023-01379-z_bib51","first-page":"e3257","article-title":"\u03b2-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies","volume":"95","author":"Ferreira","year":"2020","journal-title":"Neurology [Internet]"},{"issue":"20","key":"10.1007\/s13311-023-01379-z_bib52","first-page":"e2303","article-title":"CSF biomarkers of Alzheimer disease in patients with concomitant \u03b1-synuclein pathology","volume":"99","author":"Cousins","year":"2022","journal-title":"Neurology [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib53","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.23506","article-title":"Rapidly progressive diffuse Lewy body disease","volume":"26","author":"Gaig","year":"2011","journal-title":"Mov Disord [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib54","first-page":"201","article-title":"Rapidly progressive neurodegenerative dementias","volume":"66","author":"Josephs","year":"2009","journal-title":"Arch Neurol [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer's disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib57","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awy153","article-title":"A broader view of dementia: multiple co-pathologies are the norm","volume":"141","author":"Coulthard","year":"2018","journal-title":"Brain [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1212\/WNL.0000000000002651","article-title":"Monitoring of 30 marker candidates in early Parkinson disease as progression markers","volume":"87","author":"Mollenhauer","year":"2016","journal-title":"Neurology [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020370","article-title":"Blood contamination in CSF and its impact on quantitative analysis of alpha-synuclein","volume":"9","author":"Barkovits","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib60","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mds.27232","article-title":"Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson's disease features","volume":"33","author":"Goldman","year":"2018","journal-title":"Mov Disord [Internet]"},{"issue":"13","key":"10.1007\/s13311-023-01379-z_bib61","first-page":"85","article-title":"Preanalytical stability of CSF total and oligomeric alpha-synuclein","volume":"3","author":"Abdi","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib62","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson's disease patients","volume":"11","author":"Youssef","year":"2021","journal-title":"J Parkinsons Dis [Internet]"},{"issue":"426","key":"10.1007\/s13311-023-01379-z_bib63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2015.08.003","article-title":"Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human \u03b1-Synuclein in cerebrospinal fluid","volume":"1","author":"Kruse","year":"2015","journal-title":"J Immunol Methods"},{"key":"10.1007\/s13311-023-01379-z_bib64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","article-title":"Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease","volume":"6","author":"Parnetti","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"Pt 3","key":"10.1007\/s13311-023-01379-z_bib65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased \u03b1-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib67","first-page":"645","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Wang","year":"2014","journal-title":"Int J Neurosci [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib68","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: A systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov Disord"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib69","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid \u03b1-synuclein in prodromal and early Parkinson's disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov Disord [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int J Neurosci [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib72","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.neurobiolaging.2010.12.001","article-title":"CSF \u03b1-synuclein does not differentiate between parkinsonian disorders","volume":"33","author":"Aerts","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","article-title":"A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor","volume":"11","author":"Jankovic","year":"1996","journal-title":"Mov Disord"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib75","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ajpath.2013.12.007","article-title":"Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort","volume":"184","author":"Stewart","year":"2014","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib76","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov Disord [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib77","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease","volume":"31","author":"Hall","year":"2016","journal-title":"Mov Disord [Internet]"},{"issue":"11","key":"10.1007\/s13311-023-01379-z_bib78","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib79","first-page":"S290","article-title":"Increased CSF \u03b1-synuclein levels in Alzheimer's disease: correlation with tau levels","volume":"10","author":"Slaets","year":"2014","journal-title":"Alzheimer's Dement [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib80","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer's disease","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib81","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1017\/S1041610215000447","article-title":"Use of CSF \u03b1-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders","volume":"27","author":"Wang","year":"2015","journal-title":"Int Psychogeriatrics [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-220425","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Creutzfeldt-Jakob disease: a systematic review and meta-analysis","volume":"89","author":"Kong","year":"2022","journal-title":"J Alzheimers Dis [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib83","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0000000000001308","article-title":"Parkinson disease with REM sleep behavior disorder: features, \u03b1-synuclein, and inflammation","volume":"84","author":"Hu","year":"2015","journal-title":"Neurology [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib84","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric-and total-\u03b1-synuclein in premotor, motor and dementia stages of Parkinson's disease","volume":"262","author":"Compta","year":"2015","journal-title":"J Neurol"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib85","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol Cell Proteomics [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease: correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathol Commun [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib87","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/mds.28738","article-title":"Systematic assessment of 10 biomarker candidates focusing on \u03b1-synuclein-related disorders","volume":"36","author":"Schulz","year":"2021","journal-title":"Mov Disord"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib88","first-page":"1","article-title":"\u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med 2017 232 [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1007\/s13311-023-01379-z_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/srep40263","article-title":"Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease","volume":"7","author":"Majbour","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib91","first-page":"1","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol Neurodegener [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib92","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/mds.28611","article-title":"Cerebrospinal \u03b1-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort","volume":"36","author":"Majbour","year":"2021","journal-title":"Mov Disord [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib93","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson's disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib94","article-title":"Phospho-S129 alpha-synuclein is present in human plasma but not in cerebrospinal fluid as determined by an ultrasensitive immunoassay","volume":"13","author":"Cariulo","year":"2019","journal-title":"Front Neurosci [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib95","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","article-title":"Plasma levels of \u03b1-synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson's disease","volume":"28","author":"Chen","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.1007\/s13311-023-01379-z_bib96","article-title":"Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson's disease","volume":"10","author":"Chang","year":"2020","journal-title":"Front Neurol [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib97","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson's disease patients","volume":"11","author":"Youssef","year":"2021","journal-title":"J Parkinsons Dis [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib98","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma \u03b1-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov Disord [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib99","first-page":"1435","article-title":"The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J Neural Transm 2006 11310 [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib100","article-title":"Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson's disease","volume":"17","author":"Fan","year":"2020","journal-title":"J Neuroinflammation [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib101","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma \u03b1-synuclein predicts cognitive decline in Parkinson's disease","volume":"88","author":"Lin","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"issue":"8","key":"10.1007\/s13311-023-01379-z_bib102","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00702-013-0972-6","article-title":"Gender differences in Parkinson's disease: Focus on plasma alpha-synuclein","volume":"120","author":"Caranci","year":"2013","journal-title":"J Neural Transm [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib103","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s13273-020-00104-7","article-title":"Decreased plasma \u03b1-synuclein in idiopathic Parkinson's disease patients after adjusting hemolysis factor","volume":"16","author":"Shim","year":"2020","journal-title":"Mol Cell Toxicol [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib104","article-title":"\u03b1-Synuclein levels in blood plasma from LRRK2 mutation carriers","volume":"7","author":"Gorostidi","year":"2012","journal-title":"PLoS One [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ane.13517","article-title":"Plasma total tau predicts executive dysfunction in Parkinson's disease","volume":"145","author":"Lin","year":"2022","journal-title":"Acta Neurol Scand [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib106","first-page":"1","article-title":"A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci Reports [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib107","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/NEN.0b013e318186de48","article-title":"Lewy body pathology involves cutaneous nerves","volume":"67","author":"Ikemura","year":"2008","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"8","key":"10.1007\/s13311-023-01379-z_bib108","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/mds.25776","article-title":"Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders","volume":"29","author":"Gelpi","year":"2014","journal-title":"Mov Disord [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-171088","article-title":"Cutaneous alpha-synuclein from paraffin embedded autopsy specimens in Parkinson's disease","volume":"7","author":"Gibbons","year":"2017","journal-title":"J Parkinsons Dis [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JPD-150680","article-title":"Prevalence of submandibular gland synucleinopathy in Parkinson's disease, dementia with Lewy bodies and other Lewy body disorders","volume":"6","author":"Beach","year":"2016","journal-title":"J Parkinsons Dis [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci Lett [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J Neural Transm [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib113","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib114","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3233\/JPD-212733","article-title":"Vagus nerve and stomach synucleinopathy in Parkinson's disease, Incidental Lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis","volume":"11","author":"Beach","year":"2021","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2011.08.014","article-title":"A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease","volume":"45","author":"Pouclet","year":"2012","journal-title":"Neurobiol Dis [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib116","first-page":"e1267","article-title":"In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib117","article-title":"A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease","volume":"24","author":"Pouclet","year":"2012","journal-title":"Neurogastroenterol Motil [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40478-016-0305-8","article-title":"Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies","volume":"4","author":"Corbill\u00e9","year":"2016","journal-title":"Acta Neuropathol Commun [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib119","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JPD-160888","article-title":"Multicenter assessment of immunohistochemical methods for pathological alpha-synuclein in sigmoid colon of autopsied Parkinson's disease and control subjects","volume":"6","author":"Beach","year":"2016","journal-title":"J Parkinsons Dis [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib120","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0000000000000204","article-title":"Submandibular gland needle biopsy for the diagnosis of Parkinson disease","volume":"82","author":"Adler","year":"2014","journal-title":"Neurology [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib121","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.26476","article-title":"Peripheral synucleinopathy in early Parkinson's disease: submandibular gland needle biopsy findings","volume":"31","author":"Adler","year":"2016","journal-title":"Mov Disord [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib122","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00401-010-0665-2","article-title":"Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease","volume":"119","author":"Del Tredici","year":"2010","journal-title":"Acta Neuropathol [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib123","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/ene.13939","article-title":"Abnormal \u03b1-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility","volume":"26","author":"Donadio","year":"2019","journal-title":"Eur J Neurol [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib124","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jnen\/nlx021","article-title":"Spine topographical distribution of skin \u03b1-synuclein deposits in idiopathic Parkinson disease","volume":"76","author":"Donadio","year":"2017","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","article-title":"A new potential biomarker for dementia with Lewy bodies","volume":"89","author":"Donadio","year":"2017","journal-title":"Neurology [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib126","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","article-title":"Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease","volume":"133","author":"Doppler","year":"2017","journal-title":"Acta Neuropathol [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib127","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mds.26293","article-title":"Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy","volume":"30","author":"Doppler","year":"2015","journal-title":"Mov Disord [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","article-title":"Cutaneous neuropathy in Parkinson's disease: a window into brain pathology","volume":"128","author":"Doppler","year":"2014","journal-title":"Acta Neuropathol [Internet]"},{"issue":"8","key":"10.1007\/s13311-023-01379-z_bib129","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00702-014-1355-3","article-title":"Cutaneous autonomic denervation in Parkinson's disease","volume":"122","author":"Navarro-Otano","year":"2015","journal-title":"J Neural Transm [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neulet.2009.12.027","article-title":"Clinical availability of skin biopsy in the diagnosis of Parkinson's disease","volume":"469","author":"Miki","year":"2010","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib131","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.24567","article-title":"Skin nerve misfolded \u03b1-synuclein in pure autonomic failure and Parkinson disease","volume":"79","author":"Donadio","year":"2016","journal-title":"Ann Neurol [Internet]"},{"issue":"15","key":"10.1007\/s13311-023-01379-z_bib132","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve \u03b1-synuclein deposits: a biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio","year":"2014","journal-title":"Neurology [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib133","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1369\/0022155420960250","article-title":"Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson's disease: the implications of sample thickness on results","volume":"68","author":"Wang","year":"2020","journal-title":"J Histochem Cytochem [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib134","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jnen\/nly056","article-title":"Immunohistochemical method and histopathology judging for the systemic synuclein sampling study (S4)","volume":"77","author":"Beach","year":"2018","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"Pt 8","key":"10.1007\/s13311-023-01379-z_bib135","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/brain\/awv138","article-title":"Phosphorylated \u03b1-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy","volume":"138","author":"Zange","year":"2015","journal-title":"Brain [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib136","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","article-title":"Cutaneous neuropathy in Parkinson's disease: a window into brain pathology","volume":"128","author":"Doppler","year":"2014","journal-title":"Acta Neuropathol [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib137","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.28399","article-title":"Immunohistochemical detection of synuclein pathology in skin in idiopathic rapid eye movement sleep behavior disorder and parkinsonism","volume":"36","author":"Al-Qassabi","year":"2021","journal-title":"Mov Disord [Internet]"},{"issue":"20","key":"10.1007\/s13311-023-01379-z_bib138","first-page":"e2513","article-title":"In Vivo Diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC","volume":"96","author":"Donadio","year":"2021","journal-title":"Neurology [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib139","article-title":"Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","author":"Wang","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01379-z_bib140","article-title":"Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium","volume":"12","author":"Scott","year":"2022","journal-title":"Front Neurol [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib141","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10286-018-0581-4","article-title":"Skin nerve \u03b1-synuclein deposits in Parkinson's disease and other synucleinopathies: a review","volume":"29","author":"Donadio","year":"2019","journal-title":"Clin Auton Res [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib142","article-title":"Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients","volume":"9","author":"Iranzo","year":"2014","journal-title":"PLoS One [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib143","first-page":"E889","article-title":"Predicting phenoconversion in pure autonomic failure","volume":"95","author":"Coon","year":"2020","journal-title":"Neurology [Internet]"},{"issue":"12","key":"10.1007\/s13311-023-01379-z_bib144","article-title":"Cutaneous \u03b1-synuclein is correlated with autonomic impairment in isolated rapid eye movement sleep behavior disorder","volume":"44","author":"Miglis","year":"2021","journal-title":"Sleep [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib145","first-page":"1","article-title":"Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study \u201cFARPRESTO.\u201d","volume":"1","author":"Puligheddu","year":"2022","journal-title":"Neurol Sci [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib146","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/mds.28126","article-title":"Skin biopsy may help to distinguish multiple system atrophy-parkinsonism from Parkinson's disease with orthostatic hypotension","volume":"35","author":"Donadio","year":"2020","journal-title":"Mov Disord [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib147","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206772","article-title":"Cutaneous \u03b1-synuclein signatures in patients with multiple system atrophy and Parkinson disease","author":"Gibbons","year":"2023","journal-title":"Neurology [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib148","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib149","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis","volume":"17","author":"Velseboer","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib150","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnen\/nly074","article-title":"Skin nerve phosphorylated \u03b1-synuclein deposits in Parkinson disease with orthostatic hypotension","volume":"77","author":"Donadio","year":"2018","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib151","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jnen\/nlaa048","article-title":"A longitudinal skin biopsy study of phosphorylated alpha-synuclein in a patient with Parkinson disease and orthostatic hypotension","volume":"79","author":"Infante","year":"2020","journal-title":"J Neuropathol Exp Neurol [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib152","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acn3.51301","article-title":"Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants","volume":"8","author":"Yang","year":"2021","journal-title":"Ann Clin Transl Neurol [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib153","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/mds.28667","article-title":"\u03b1\u2010synuclein deposition in sympathetic nerve fibers in genetic forms of Parkinson's disease","volume":"36","author":"Isonaka","year":"2021","journal-title":"Mov Disord [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib154","article-title":"Dermal phospho-alpha-synuclein deposition in patients with Parkinson's disease and mutation of the glucocerebrosidase gene","volume":"9","author":"Doppler","year":"2018","journal-title":"Front Neurol [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2019.05.038","article-title":"Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers","volume":"65","author":"Carmona-Abellan","year":"2019","journal-title":"Parkinsonism Relat Disord [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib156","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson's disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov Disord [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib157","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12031-011-9696-y","article-title":"Clinical and pathological characteristics of LRRK2 G2019S patients with PD","volume":"47","author":"Poulopoulos","year":"2012","journal-title":"J Mol Neurosci [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib158","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/bmm-2021-0646","article-title":"Synuclein-One study: Skin biopsy detection of phosphorylated \u03b1-synuclein for diagnosis of synucleinopathies","volume":"16","author":"Gibbons","year":"2022","journal-title":"Biomark Med [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib159","article-title":"Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium","volume":"12","author":"Scott","year":"2021","journal-title":"Front Neurol [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib160","first-page":"3916","article-title":"Prion-like seeding of misfolded alpha-synuclein in the brains of dementia with Lewy body patients in RT-QUIC","volume":"55","author":"Sano","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib161","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib162","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"7794","key":"10.1007\/s13311-023-01379-z_bib163","first-page":"273","article-title":"Discriminating \u03b1-synuclein strains in Parkinson's disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nat 2020 5787794 [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib164","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-8820-4_2","article-title":"Ultrasensitive RT-QuIC seed amplification assays for disease-associated tau, alpha-synuclein, and prion aggregates","volume":"1873","author":"Saijo","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib165","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha\u2010synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann Neurol [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib166","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson's disease","volume":"34","author":"Kang","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib167","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol Commun [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib168","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib169","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib170","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib171","series-title":"Techniques in experimental virology","first-page":"183","article-title":"Animal virus titration techniques","volume":"Vol. 178","author":"Dougherty","year":"1964"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib172","article-title":"Diagnostic value of skin RT-QuIC in Parkinson's disease: a two-laboratory study","volume":"7","author":"Kuzkina","year":"2021","journal-title":"NPJ Park Dis [Internet]"},{"issue":"9","key":"10.1007\/s13311-023-01379-z_bib173","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/mds.28651","article-title":"RT-QuIC detection of pathological \u03b1-synuclein in skin punches of patients with Lewy body disease","volume":"36","author":"Mammana","year":"2021","journal-title":"Mov Disord [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib174","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathol Commun [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib175","doi-asserted-by":"crossref","unstructured":"Iranzo A, Mammana A, Mu\u00f1oz-Lopetegi A, Dellavalle S, May\u00e0 ; Gerard, Rossi M, et al. Misfolded \u03b1-synuclein assessment in skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. 2023.","DOI":"10.1212\/WNL.0000000000207147"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib176","first-page":"1","article-title":"Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib177","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","article-title":"Efficient RT-QuIC seeding activity for \u03b1-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy","volume":"8","author":"De Luca","year":"2019","journal-title":"Transl Neurodegener [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib178","article-title":"Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"3","author":"Perra","year":"2021","journal-title":"Brain Commun [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib179","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/brain\/awab005","article-title":"Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder","volume":"144","author":"Stefani","year":"2021","journal-title":"Brain [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib180","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/mds.27907","article-title":"\u03b1-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients","volume":"35","author":"Manne","year":"2020","journal-title":"Mov Disord"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib181","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/mds.28976","article-title":"Diagnostic value of salivary real-time quaking-induced conversion in Parkinson's disease and multiple system atrophy","volume":"37","author":"Luan","year":"2022","journal-title":"Mov Disord [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib182","article-title":"Salivary \u03b1-synuclein RT-QuIC correlates with disease severity in de novo Parkinson's disease","author":"Vivacqua","year":"2022","journal-title":"Mov Disord [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib183","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.23838","article-title":"Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease","volume":"27","author":"Shannon","year":"2012","journal-title":"Mov Disord"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib184","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib185","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archneur.63.3.370","article-title":"Lewy body pathology in familial Alzheimer disease: evidence for disease-and mutation-specific pathologic phenotype","volume":"63","author":"Leverenz","year":"2006","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib186","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1385\/JMN:17:2:225","article-title":"Lewy body pathology in Alzheimer's disease","volume":"17","author":"Kotzbauer","year":"2001","journal-title":"J Mol Neurosci [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib187","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3233\/JAD-170914","article-title":"Influence of Lewy pathology on Alzheimer's disease phenotype: a retrospective clinico-pathological study","volume":"63","author":"Roudil","year":"2018","journal-title":"J Alzheimers Dis [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib188","article-title":"Performance of \u03b1Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease","volume":"10","author":"Hall","year":"2022","journal-title":"Acta Neuropathol Commun [Internet]"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib189","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.26453","article-title":"\u03b1-Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1-synuclein in the context of co-pathology and non-LBD diagnoses","volume":"92","author":"Arnold","year":"2022","journal-title":"Ann Neurol [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-015-0101-x","article-title":"Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly","volume":"7","author":"Zaccai","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib191","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1440-1789.2005.00644.x","article-title":"Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject","volume":"25","author":"Parkkinen","year":"2005","journal-title":"Neuropathology"},{"issue":"24","key":"10.1007\/s13311-023-01379-z_bib192","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","article-title":"Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease","volume":"79","author":"Milber","year":"2012","journal-title":"Neurology"},{"issue":"13","key":"10.1007\/s13311-023-01379-z_bib193","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","article-title":"Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort","volume":"70","author":"Zaccai","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-023-01379-z_bib194","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib195","first-page":"1","article-title":"Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies","volume":"9","author":"Brockmann","year":"2021","journal-title":"Acta Neuropathol Commun [Internet]"},{"issue":"2","key":"10.1007\/s13311-023-01379-z_bib196","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.29284","article-title":"Brain and cerebrospinal fluid \u03b1-synuclein real-time quaking-induced conversion identifies Lewy body pathology in LRRK2-PD","volume":"38","author":"Garrido","year":"2023","journal-title":"Mov Disord [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib197","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"The Lancet Neurology"},{"key":"10.1007\/s13311-023-01379-z_bib198","first-page":"1","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","author":"Concha-Marambio","year":"2023","journal-title":"Nat Protoc 2023 [Internet]"},{"issue":"8","key":"10.1007\/s13311-023-01379-z_bib199","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","article-title":"New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes","volume":"72","author":"Fereshtehnejad","year":"2015","journal-title":"JAMA Neurol [Internet]"},{"issue":"7","key":"10.1007\/s13311-023-01379-z_bib200","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib201","article-title":"Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design","author":"Toledo","year":"2022","journal-title":"Alzheimer's Dement [Internet]"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib202","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp.2009.199950","article-title":"CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study","volume":"81","author":"Alves","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1007\/s13311-023-01379-z_bib203","first-page":"1277","article-title":"Association of cerebrospinal fluid beta-amyloid 1\u201342, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol"},{"issue":"15","key":"10.1007\/s13311-023-01379-z_bib204","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/mds.23287","article-title":"CSF A\u03b242 and tau in Parkinson's disease with cognitive impairment","volume":"25","author":"Montine","year":"2010","journal-title":"Mov Disord"},{"issue":"8","key":"10.1007\/s13311-023-01379-z_bib205","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib206","first-page":"1","article-title":"Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis","volume":"7","author":"Hatcher-Martin","year":"2021","journal-title":"NPJ Park Dis [Internet]"},{"issue":"15","key":"10.1007\/s13311-023-01379-z_bib207","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease","volume":"24","author":"Compta","year":"2009","journal-title":"Mov Disord"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib208","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/Abeta42 predict cognitive decline in Parkinson's disease","volume":"21","author":"Liu","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib209","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","article-title":"Beta-amlyoid 1\u201342 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia","volume":"22","author":"Mollenhauer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib210","first-page":"1","article-title":"Temporal trajectory of biofluid markers in Parkinson's disease","volume":"11","author":"Baek","year":"2021","journal-title":"Sci Reports [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib211","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005166","article-title":"CSF tau and amyloid-beta predict cerebral synucleinopathy in autopsied Lewy body disorders","author":"Irwin","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib212","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch Neurol"},{"issue":"17","key":"10.1007\/s13311-023-01379-z_bib213","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology [Internet]"},{"issue":"11","key":"10.1007\/s13311-023-01379-z_bib214","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib215","first-page":"1","article-title":"Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease","volume":"11","author":"Chen","year":"2021","journal-title":"Transl Psychiatry [Internet]"},{"issue":"5","key":"10.1007\/s13311-023-01379-z_bib216","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib217","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00702-016-1650-2","article-title":"Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease","volume":"124","author":"Ding","year":"2017","journal-title":"J Neural Transm [Internet]"},{"key":"10.1007\/s13311-023-01379-z_bib218","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2022.05.022","article-title":"Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers","volume":"100","author":"Walker","year":"2022","journal-title":"Parkinsonism Relat Disord [Internet]"},{"issue":"3","key":"10.1007\/s13311-023-01379-z_bib219","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma phospho-tau identifies Alzheimer's co-pathology in patients with Lewy body disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov Disord [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol [Internet]"},{"issue":"6","key":"10.1007\/s13311-023-01379-z_bib221","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jnc.15601","article-title":"Plasma \u03b1-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease","volume":"161","author":"Ren","year":"2022","journal-title":"J Neurochem [Internet]"},{"issue":"1","key":"10.1007\/s13311-023-01379-z_bib222","first-page":"1","article-title":"Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease","volume":"8","author":"Batzu","year":"2022","journal-title":"npj Park Dis 2022 81 [Internet]"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01379-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:16:38Z","timestamp":1761808598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":222,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1878747923019050"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01379-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluid and Biopsy Based Biomarkers in Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01379-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}